<DOC>
	<DOCNO>NCT00471848</DOCNO>
	<brief_summary>To assess tolerability effectiveness rabbit antithymocyte globulin ( ATG , Thymoglobuline ) ciclosporin first line treatment patient acquire severe aplastic anaemia , patient non-severe aplastic anaemia transfusion dependent .</brief_summary>
	<brief_title>Rabbit Antithymocyte Globulin ( Thymoglobuline ) With Ciclosporin Patients With Acquired Aplastic Anaemia</brief_title>
	<detailed_description>Traditionally horse antithymocyte globulin ( ATG ) prefer animal source ATG first line treatment acquire aplastic anaemia ( AA ) patient ineligible bone marrow transplantation ( BMT ) . For severe AA ( SAA ) combination ATG Ciclosporin ( CSA ) result response 60-75 % patient response superior use either agent alone . The addition granulocyte colony stimulate factor ( G-CSF ) combination ATG CSA far show significant benefit term response survival , EBMT prospective study currently evaluate large number patient . For patient NSAA transfusion dependent , combination ATG CSA show superior CSA alone EBMT prospective randomise study , high response rate , superior blood count improve disease free survival use combination ATG CSA . There phase II study rabbit ATG ( Thymoglobuline速 ) treatment AA first line therapy . Preliminary result small single centre study compare horse ATG ( ATGAM ) rabbit ATG ( Fresenius ) child show response rate 93 % 47 % , respectively , likely different preparation rabbit ATG vary efficacy . Rabbit ATG commonly use second course follow relapse lack response first course horse ATG . Rabbit ATG combination CSA G-CSF use patient SAA fail respond course horse ATG CSA G-CSF . Overall response ( transfusion independence ) see 23/30 ( 77 % ) patient median 95 day complete response ( neutrophils &gt; 2.0 , haemoglobin &gt; 11 , platelet &gt; 100 ) 9/30 ( 30 % ) . Rabbit ATG well tolerate ; anaphylaxis severe side effect report . Another study 43 patient treated rabbit ATG CSA follow non-response relapse horse ATG CSA , show 30 % response rate among non-responding patient 65 % response rate relapse patient . Studies compare antibody specificity Thymoglobuline速 Lymphoglobuline速 broad agreement , ( ) Lymphoglobuline速 few study report old , product old less extensively develop ( b ) antibodies certain epitope inconsistently present ( c ) antibody specificity examine study ( ) different method test use . There view immunogen animal specie important create difference different ATGs .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>1 . Must fulfil definition aplastic anaemia : There must least two follow : haemoglobin &lt; 10g/dl platelet count &lt; 50 x 109/l neutrophil count &lt; 1.5 x 109/l , hypocellular bone marrow bone marrow biopsy SAA define hypocellular bone marrow &lt; 25 % cellularity two following : neutrophil count &lt; 0.5 x 109/l platelet &lt; 20 x 109/l reticulocyte &lt; 20 x 109/l NSAA define hypocellular bone marrow cytopenia least two cell line neutrophil count &gt; 0.5 x 109/l , red cell and/or platelet transfusion dependence 2 . Have acquire aplastic anaemia 3 . Time diagnosis study registration maximum 6 month 4 . No prior treatment except haemopoietic growth factor give four week , androgens 5 . Age minimum 16 year upper age limit 1 . Eligibility HLAmatched sibling donor transplant SAA patient 2 . Prior therapy ATG CSA 3 . Haematopoeitic growth factor 4 week study enrolment 4 . Diagnosis Fanconi anaemia , dyskeratosis congenita congenital bone marrow failure syndrome 5 . Evidence myelodysplastic disease 6 . Paroxysmal nocturnal haemoglobinuria evidence significant haemolysis , history PNH associate thrombosis PNH clone &gt; 50 % flow cytometry 7 . Diagnosis previous history carcinoma ( except local cervical , basal cell , squamous cell , melanoma ) 8 . Subject pregnant ( e.g . positive HCG test ) breast feed 9 . Severe uncontrolled infection unexplained fever &gt; 38oC 10 . Subjects hepatic , renal cardiac , metabolic concurrent disease severity life expectancy le 3 month</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Thymoglobuline</keyword>
	<keyword>Rabbit ATG</keyword>
	<keyword>Ciclosporin</keyword>
	<keyword>Aplastic Anemia</keyword>
</DOC>